ArticleMedical mycology2020
Cathelicidin-inspired antimicrobial peptides as novel antifungal compounds.
Article in Medical mycology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Evaluation of safety and efficacy of calcipotriol 0.005% cream versus terbinafine hydrochloride 1% cream in treatment of onychomycosis; a randomized split body comparative pilot study.Archives of dermatological research · 2025Trial
- Managing Malassezia species and related infections: new insights into recent natural and synthetic antifungal compounds and their mechanism of action.Molecular diversity · 2026Review
- Inhibition of Candida albicans yeast-to-hypha transition and virulence by cyclic dipeptides derived from probiotic Aeromonas veronii V03.Scientific reports · 2026Article
- Antimicrobial Peptides Versus Antibiotics in Farm Animal Production.Antibiotics (Basel, Switzerland) · 2025Review
- Solid-State NMR Reveals Reorganization of the Aspergillus fumigatus Cell Wall Due to a Host-Defence Peptide.Angewandte Chemie (International ed. in English) · 2025Article
- Self-assembled nanopeptide dendrites with high antifungal activity and protease hydrolytic stability for fungal keratitis treatment.Journal of nanobiotechnology · 2025Article
- Advances in Antimicrobial Peptides: Mechanisms, Design Innovations, and Biomedical Potential.Molecules (Basel, Switzerland) · 2025Review
- Double-Layer Magnetic Microspheres with Dual Drug Delivery of Antibacterial and Maintenance Agents for the Treatment ofACS omega · 2025Article
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Marsupial cathelicidins: characterization, antimicrobial activity and evolution in this unique mammalian lineage.Frontiers in immunology · 2025Article
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- Control of Postharvest Green Mold in Citrus by the Antimicrobial Peptide BP15 and Its Lipopeptides.Journal of fungi (Basel, Switzerland) · 2024Article
- Immunity to fungi and vaccine considerations.Cell host & microbe · 2024Review
- Biomimetic Antifungal Materials: Countering the Challenge of Multidrug-Resistant Fungi.Biomimetics (Basel, Switzerland) · 2024Review
- Exploring the Therapeutic Potential of Scorpion-Derived Css54 Peptide Against Candida albicans.Journal of microbiology (Seoul, Korea) · 2024Article
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.World journal of microbiology & biotechnology · 2023Review
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Fungicidal activity of human antimicrobial peptides and their synergistic interaction with common antifungals against multidrug-resistant Candida auris.International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- Probing Cell-Surface Interactions in Fungal Cell Walls by High-ResolutionChemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections in humans are increasing worldwide and are currently mostly treated with a relative limited set of antifungals. Resistance to antifungals is increasing, for example, in Aspergillus fumigatus and Candida auris, and expected to increase for many medically relevant fungal species in the near future. We have developed and patented a set of cathelicidin-inspired antimicrobial peptides termed 'PepBiotics'. These peptides were initially selected for their bactericidal activity against clinically relevant Pseudomonas aeruginosa and Staphylococcus aureus isolates derived from patients with cystic fibrosis and are active against a wide range of bacteria (ESKAPE pathogens). We now report results from studies that were designed to investigate the antifungal activity of PepBiotics against a set of medically relevant species encompassing species of Aspergillus, Candida, Cryptococcus, Fusarium, Malassezia, and Talaromyces. We characterized a subset of PepBiotics and show that these peptides strongly affected metabolic activity and/or growth of a set of medically relevant fungal species, including azole-resistant A. fumigatus isolates. PepBiotics showed a strong inhibitory activity against a large variety of filamentous fungi and yeasts species at low concentrations (≤1 μM) and were fungicidal for at least a subset of these fungal species. Interestingly, the concentration of PepBiotics required to interfere with growth or metabolic activity varied between different fungal species or even between isolates of the same fungal species. This study shows that PepBiotics display strong potential for use as novel antifungal compounds to fight a large variety of clinically relevant fungal species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.